Reexamine the effect of the Inflation Reduction Act

Life sciences companies are confronting the impact of the Inflation Reduction Act (IRA) of 2022, especially the Centers for Medicare & Medicaid Services’ (CMS) drug price negotiation program. As you enter negotiations and prepare evidence for CMS, it’s important to think about the current state of your products. Using only clinical trial data that’s over 10 years old won’t work. To build your case with stakeholders, you need:

• Timely, real-world information on product use and performance in the Medicare population
• The ability to describe the value of that evidence

You should be able to answer a range of questions about your products and pipeline strategy in a post-IRA world. Read this overview to see how real-world data and evidence, research consulting and financial modelling services can help strengthen your product value story.

Download overview